Incyte (INCY) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Twist Bioscience (TWST) has outperformed Incyte (INCY) over the past year, gaining 363.7% versus a gain of 32.1%. Over five years, INCY leads with a +72.0% price change compared with +34.8% for TWST. Incyte is the larger company by market cap ($22.90 billion vs $11.06 billion), about 2.1 times the size.
Incyte converts more of its revenue into profit, with a net margin of 25.0% versus -20.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCY | TWST |
|---|---|---|
| Share price | $113.00 | $166.84 |
| Market cap | $22.90B | $11.06B |
| 1-day change | +0.22% | +9.73% |
| YTD return | +14.15% | +379.35% |
| 1-year return | +32.06% | +363.71% |
| 5-year return | +71.98% | +34.80% |
| P/E ratio (TTM) | 14.39 | — |
| Forward P/E | 12.92 | — |
| EPS (TTM) | $7.85 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.14B | $376.57M |
| Revenue growth (YoY) | +21.22% | +20.32% |
| Net income (latest FY) | $1.29B | $-77.67M |
| Gross margin | 92.76% | 50.72% |
| Operating margin | 29.46% | -36.18% |
| Net margin | 25.03% | -20.63% |
| 52-week high | $132.60 | $219.71 |
| 52-week low | $82.82 | $23.30 |
| Distance from 52-week high | -14.79% | -24.06% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +14.28% | -9.90% |
| Average volume | 1.63M | 2.04M |
| Shares outstanding | 202.70M | 66.30M |
| Employees | 2,844 | 979 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Incyte is about 2.1 times larger than Twist Bioscience by market value ($22.90B vs $11.06B).
- TWST has outperformed INCY by 331.7 percentage points over the past year.
- Incyte is more profitable, keeping 25.0 cents of every revenue dollar as net income versus -20.6 cents for Twist Bioscience.
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 979 employees
INCY vs TWST FAQ
Which is bigger, Incyte or Twist Bioscience?
Incyte (INCY) is larger, with a market capitalization of $22.90B compared with $11.06B for Twist Bioscience (TWST).
Which stock has performed better over the past year, INCY or TWST?
TWST returned +363.71% over the past 12 months, compared with +32.06% for INCY (price return, excluding dividends). Past performance does not predict future results.
Are Incyte and Twist Bioscience in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Incyte and Biotechnology: Biological Products (No Diagnostic Substances) for Twist Bioscience.